TDO2+ myofibroblasts mediate immune suppression in malignant transformation of squamous cell carcinoma
Simeng Hu1, Huanzi Lu2, Wenqiang Xie2
1Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Academy for Advanced Interdisciplinary Studies (AAIS), and Peking University-Tsinghua University-National Institute of Biological Sciences Joint Graduate Program (PTN), Peking University, Beijing, China.
Abstract:
Characterization of the dynamic change in the immunological landscape during malignant transformation from precancerous lesions to cancerous lesions in squamous cell carcinoma (SCC) is critical for the application of immunotherapy. Here, we performed single-cell RNA-Seq (scRNA-Seq) of 131,702 cells from 13 cancerous tissues of oral squamous cell carcinoma (OSCC), 3 samples of precancerous oral leukoplakia, and 8 adjacent normal samples. We found that tumor-infiltrating CD4+ and CD8+ T cells were functionally inhibited by immunosuppressive ligands expressed on various types of myeloid cells or neutrophils in the process of oral carcinogenesis. Notably, we identified a subset of myofibroblasts that exclusively expressed tryptophan 2,3-dioxygenase (TDO2). These TDO2+ myofibroblasts were located distally from tumor nests, and both CD4+ and CD8+ T cells were enriched around them. Functional experiments revealed that TDO2+ myofibroblasts were more likely to possess the ability for chemotaxis toward T cells but induced the transformation of CD4+ T cells into Tregs and caused CD8+ T cell dysfunction. We further showed that use of the TDO2 inhibitor LM10 attenuated the inhibitory states of T cells, restored the T cell antitumor response, and prevented the progression of OSCC malignant transformation in murine models. Our study reveals a multistep transcriptomic landscape of OSCC and demonstrates that TDO2+ myofibroblasts are potential targets for immunotherapy.
Insights
Immunosuppressive cells called TDO2+ myofibroblasts hinder anti-tumor T cells in oral cancer. Inhibiting TDO2 may restore T cell function and prevent oral squamous cell carcinoma progression.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Understanding immune changes during oral cancer development is key for effective immunotherapy.
- Oral squamous cell carcinoma (OSCC) progression involves complex immune microenvironment alterations.
Purpose of the Study:
- To characterize the dynamic immunological landscape during oral carcinogenesis.
- To identify novel cellular targets for OSCC immunotherapy.
Main Methods:
- Single-cell RNA sequencing (scRNA-Seq) of 131,702 cells from OSCC, precancerous lesions, and normal tissues.
- Functional experiments assessing T cell-myofibroblast interactions.
- In vivo studies using a TDO2 inhibitor (LM10) in murine models.
Main Results:
- Tumor-infiltrating CD4+ and CD8+ T cells are functionally inhibited by immunosuppressive myeloid cells and neutrophils.
- A novel subset of TDO2+ myofibroblasts was identified, located away from tumor nests.
- TDO2+ myofibroblasts promote T cell dysfunction, Treg differentiation, and OSCC progression.
- TDO2 inhibition (LM10) restored T cell antitumor activity and prevented malignant transformation in mice.
Conclusions:
- TDO2+ myofibroblasts represent a significant immunosuppressive component in oral carcinogenesis.
- Targeting TDO2+ myofibroblasts offers a promising therapeutic strategy for OSCC immunotherapy.
Related Concept Videos
The Tumor Microenvironment
Abnormal Proliferation
Tumor Immunotherapy
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
TGF - β Signaling Pathway
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...


